BL1 COST-EFFECTIVENESS, VALUE OF INFORMATION, AND BUDGET IMPACT OF CERTOLIZUMAB PEGOL COMPARED TO SUBCUTANEOUS TUMOR NECROSIS FACTOR (TNF) INHIBITORS AND METHOTREXATE IN THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN FINLAND
Abstract
Authors
EJ Soini T Hallinen M Taiha V Honkanen